Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days

被引:39
|
作者
Kallner, H. Kopp [1 ]
Fiala, C. [2 ]
Stephansson, O. [1 ,3 ]
Gemzell-Danielsson, K. [1 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Dept Womens & Childrens Hlth, Div Obstet & Gynaecol, S-17176 Stockholm, Sweden
[2] Gynmed Clin, A-1150 Vienna, Austria
[3] Karolinska Univ Hosp, Karolinska Inst, Dept Med, Clin Epidemiol Unit, S-17176 Stockholm, Sweden
基金
瑞典研究理事会;
关键词
mifepristone; home administration; medical abortion; termination of pregnancy; acceptability; MIFEPRISTONE; ACCEPTABILITY; COMBINATION; PREGNANCY; REGIMEN; TRIAL;
D O I
10.1093/humrep/deq037
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Home use of misoprostol for termination of pregnancy is still controversial in many countries. Acceptability of home use of misoprostol has been investigated in pregnancies below 49 days gestation. In this study, we aimed to assess efficacy, feasibility and acceptability of home use of vaginal misoprostol for medical termination of pregnancy at 50-63 days compared with gestation of below 50 days among women who chose to administer misoprostol at home. In this prospective study, mifepristone 200 mg was given in hospital under nursing supervision in the university hospital outpatient family planning clinic. Women self-administered misoprostol 800 mu g vaginally 36-48 h later at home. Follow-up was 2 weeks later. Women with gestation of 50-63 days on the day of mifepristone administration were compared with women with gestation of below 50 days. Efficacy and feasibility were assessed by review of patient records and questionnaires. Acceptability was assessed using questionnaires where women reported on future choice of abortion method were they to have another abortion. Among the 2992 women who had a medical abortion during the study period, 395 women chose to administer misoprostol at home and were included in the study. A total of 203 women were below 50 days gestation and 192 were between 50 and 63 days gestation. Efficacy was 97.5% and did not differ between the groups. Surgical intervention was needed in 10 patients, of whom four were in the lower gestational band (P = 0.36). No serious adverse events or blood transfusions were reported. Preference for home administration of misoprostol, were they to have another induced abortion in the future, was high, 92.3 and 86.6% respectively, and did not differ between the groups (P = 0.097). Need for extra analgesia significantly influenced women's experiences in both gestational groups. Medical abortion with mifepristone followed by home administration of vaginal misoprostol is safe and highly acceptable also to women with gestational length of 50-63 days as compared with shorter gestations. Efficacy, acceptability and preference for future place of administration of misoprostol, were women to have another abortion, did not differ between women with gestation below 50 days or between 50 and 63 days.
引用
收藏
页码:1153 / 1157
页数:5
相关论文
共 50 条
  • [21] Predictors of dilation and curettage after medical abortion through 63 days gestation
    Hohmann, H. L.
    Reeves, M. F.
    Creinin, M. D.
    CONTRACEPTION, 2007, 76 (02) : 163 - 164
  • [22] Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days
    Gatter, Mary
    Cleland, Kelly
    Nucatola, Deborah L.
    CONTRACEPTION, 2015, 91 (04) : 269 - 273
  • [23] Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy
    Schaff, EA
    Fielding, SL
    Westhoff, C
    CONTRACEPTION, 2002, 66 (04) : 247 - 250
  • [24] Women's experiences of self-administration of misoprostol at home as part of early medical abortion: a qualitative evaluation
    Harden, Jeni
    Ancian, Julie
    Cameron, Sharon
    Boydell, Nicola
    BMJ SEXUAL & REPRODUCTIVE HEALTH, 2021, 47 (02) : 144 - 149
  • [25] Acceptability and feasibility of outpatient medical abortion with mifepristone and misoprostol up to 70 days gestation in Singapore
    Tan, Yi-Ling
    Singh, Kuldip
    Tan, Kok Hian
    Gosavi, Arundhati
    Koh, Daniel
    Abbas, Dina
    Winikoff, Beverly
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2018, 229 : 144 - 147
  • [26] Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days
    Schaff, EA
    Fielding, SL
    Eisinger, SH
    Stadalius, LS
    Fuller, L
    CONTRACEPTION, 2000, 61 (01) : 41 - 46
  • [27] 25 mg or 50 mg of oral methotrexate followed by vaginal misoprostol 7 days after for early abortion -: A randomized trial
    Esteve, JLC
    Varela, L
    Velazco, A
    Tanda, R
    Sánchez, C
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1999, 47 (03) : 182 - 187
  • [28] Mifepristone followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhoea in a general practice in Curacao
    Boersma, Adriana A.
    Jong, Betty Meyboom-de
    Kleiverda, Gunilla
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2011, 16 (02): : 61 - 66
  • [29] THE EXTENDED GESTATIONAL AGE MEDICAL ABORTION STUDY: THE EFFECTIVENESS OF MEDICAL ABORTION WITH 200 MG MIFEPRISTONE AND 400 MCG SUBLINGUAL MISOPROSTOL AT 57-63 DAYS VS. 64-70 DAYS GESTATION
    Bracken, H.
    Attia, M. B.
    Chelli, H.
    Dabash, R.
    Hajri, S.
    Mundle, S.
    Platais, I
    Posohova, S.
    Raghavan, S.
    Shah, M.
    Swica, Y.
    Tsereteli, T.
    Tsertsvadze, G.
    Winikoff, B.
    Zerarmdini, D.
    CONTRACEPTION, 2011, 84 (03) : 303 - 303
  • [30] Two prophylactic pain management regimens for medical abortion ≤63 days' gestation with mifepristone and misoprostol: A multicenter, randomized, placebo-controlled trial
    Dragoman, Monica V.
    Grossman, Daniel
    Nguyen, My Huong
    Habib, Ndema
    Kapp, Nathalie
    Tamang, Anand
    Bessenaar, Tshego
    Lan Dung Duong
    Gautam, Jageshwor
    Yoko, Jean-Louis
    Minh Hong
    Gulmezoglu, Metin
    CONTRACEPTION, 2021, 103 (03) : 163 - 170